The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD)

Halbreich, Uriel; Borenstein, Jeff; Pearlstein, Terry; Kahn, Linda S.

doi:10.1016/s0306-4530(03)00098-2

Cited by 432 publications

(511 citation statements)

References 73 publications

Supporting

Mentioning

460

Contrasting

Unclassified

Order By: Relevance

“…For example, debates still continue around elements of the DSM criteria for PMDD, which are described by some as potentially arbitrary (e.g. too many symptoms necessary) and may lead to undercounting (Halbreich, et al, 2003)." Such arguments coupled with an emerging understanding of the cause of the condition may explain why many of the websites do not provide comprehensive information for the website user.…”

Section: Discussionmentioning

confidence: 99%

What Are Women Being Exposed to? A Review of the Quality, Content and Ownership of Websites on Premenstrual Dysphoric Disorder

Hardy

Sillence

2016

Women's Health Issues

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

What Are Women Being Exposed to? A Review of the Quality, Content and Ownership of Websites on Premenstrual Dysphoric Disorder

Hardy

Sillence

2016

Women's Health Issues

View full text Add to dashboard Cite

show abstract

“…Up to 30% felt them to be considerably bothersome, whilst a smaller proportion of women (3-8%) who experienced severe and debilitating symptoms, were diagnosed with premenstrual dysphoric disorder (PMDD; American Psychiatric Association, 2013), which is considered a distinct psychiatric disorder (Halbreich et al, 2003;Tschudin et al, 2010;Wittchen et al, 2002). It is not clear however, whether PMS and PMDD are separate entities or whether PMDD is an extreme form of PMS.…”

Section: Premenstrual Dysphorias Are Extremely Common In Large Survementioning

confidence: 99%

A specific profile of luteal phase progesterone is associated with the development of premenstrual symptoms

Lovick

Guapo

Anselmo-Franci

et al. 2017

Psychoneuroendocrinology

View full text Add to dashboard Cite

Lovick, T., Guapo, V. G., Amselmo-Franci, J. A., Loureiro, C. M., Faleiros, C. M., Del Ben, C. M., & Brandão, M. L. (2017). A specific profile of luteal phase progesterone is associated with the development of premenstrual symptoms. Psychoneuroendocrinology, 75,[86][87][88][89][90] University of Bristol -Explore Bristol Research General rightsThis document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/pure/about/ebr-terms There is a consensus that the development of premenstrual dysphoric states is related to cyclical change in gonadal hormone secretion during the menstrual cycle.However, results from studies seeking to link symptom severity to luteal phase progesterone concentration have been equivocal. In the present study we evaluated not only the absolute concentrations of progesterone but also the kinetics of the change in progesterone concentration in relation to development of premenstrual symptoms during the last 10 days of the luteal phase in a population of 46 healthy young adult Brazilian women aged 18-39 years, mean 26.5±6.7 years. In participants who developed symptoms of premenstrual distress, daily saliva progesterone concentration remained stable during most of the mid-late luteal phase, before declining sharply during the last 3 days prior to onset of menstruation. In contrast, progesterone concentration in asymptomatic women underwent a gradual decline over the last 8 days prior to menstruation. Neither maximum nor minimum concentrations of progesterone in the two groups were related to the appearance or severity of premenstrual symptoms. We propose that individual differences in the kinetics of progesterone secretion and/or metabolism may confer differential susceptibility to the development of premenstrual syndrome.

show abstract

“…The prevalence of PMDD is 2-8% of women and a less severe phenotype of PMS is present in 15-25% of women (Wittchen 2002;Chawla et al 2002;Backstrom et al 2003;Halbreich et al 2003). Despite the high prevalence of PMDD, the World Health Organization (WHO) did not include PMDD or PMS in the comprehensive report regarding the economic burden of mental health disorders.…”

Section: Changes In δ Subunit-containing Gabaars During Changes In Stmentioning

confidence: 99%

“…During the reproductive age of women (14-51, a conservative estimate), an average of 1,400 workdays/person are estimated to be lost due to PMS/PMDD, corresponding to 3.84 years of disability (DALY). In the United States alone this would add up to 14,492,465 DALYs, resulting in a significant economic burden (Halbreich et al, 2003). In addition to the loss of productivity, health care costs for the treatment of PMDD-associated symptoms such as depression and headaches, also add to the economic impact of the disease (Halbreich et al 2003).…”

Section: Changes In δ Subunit-containing Gabaars During Changes In Stmentioning

confidence: 99%

“…In the United States alone this would add up to 14,492,465 DALYs, resulting in a significant economic burden (Halbreich et al, 2003). In addition to the loss of productivity, health care costs for the treatment of PMDD-associated symptoms such as depression and headaches, also add to the economic impact of the disease (Halbreich et al 2003). Present treatment of PMDD is mainly limited to SSRI such as Zoloft, in spite of the fact that there seems to be no serotonergic abnormality in affected women (Freeman 2004).…”

Section: Changes In δ Subunit-containing Gabaars During Changes In Stmentioning

confidence: 99%

See 1 more Smart Citation

Extrasynaptic GABAA receptors in the crosshairs of hormones and ethanol

Módy¹

2008

Neurochemistry International

View full text Add to dashboard Cite

Gamma-aminobutyric acid (GABA) is the main chemical inhibitory neurotransmitter in the brain. In the central nervous system (CNS) it acts on two distinct types of receptor: an ion channel, i.e., an "ionotropic" receptor permeable to Cl − and HCO 3 − (GABA A receptors) and a G-protein coupled "metabotropic" receptor that is linked to various effector mechanisms (GABA B receptors). This review will summarize novel developments in the physiology and pharmacology of GABA A receptors (GABA A Rs), specifically those found outside synapses. The focus will be on a particular combination of GABA A R subunits sensitive to ovarian and adrenal cortical steroid hormone metabolites that are synthesized in the brain (neurosteroids) and to sobriety impairing concentrations of ethanol. These receptors may be the final common pathway for interactions between ethanol and ovarian and stress-related neurosteroids.

show abstract

The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD)

Cited by 432 publications

References 73 publications

What Are Women Being Exposed to? A Review of the Quality, Content and Ownership of Websites on Premenstrual Dysphoric Disorder

What Are Women Being Exposed to? A Review of the Quality, Content and Ownership of Websites on Premenstrual Dysphoric Disorder

A specific profile of luteal phase progesterone is associated with the development of premenstrual symptoms

Extrasynaptic GABAA receptors in the crosshairs of hormones and ethanol

Contact Info

Product

Resources

About